JP5057353B2 - ニコチン酸化合物を使用するレプチンレベル増大のための方法 - Google Patents

ニコチン酸化合物を使用するレプチンレベル増大のための方法 Download PDF

Info

Publication number
JP5057353B2
JP5057353B2 JP2002571051A JP2002571051A JP5057353B2 JP 5057353 B2 JP5057353 B2 JP 5057353B2 JP 2002571051 A JP2002571051 A JP 2002571051A JP 2002571051 A JP2002571051 A JP 2002571051A JP 5057353 B2 JP5057353 B2 JP 5057353B2
Authority
JP
Japan
Prior art keywords
leptin
nicotinic acid
leptin levels
nicotinate
mice
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2002571051A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004519488A5 (enExample
JP2004519488A (ja
Inventor
エレイン ジャコブソン，
マイロン ケイ． ジャコブソン，
ヒュンテ キム，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Arizona
Original Assignee
University of Arizona
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23047813&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP5057353(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by University of Arizona filed Critical University of Arizona
Publication of JP2004519488A publication Critical patent/JP2004519488A/ja
Publication of JP2004519488A5 publication Critical patent/JP2004519488A5/ja
Application granted granted Critical
Publication of JP5057353B2 publication Critical patent/JP5057353B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2002571051A 2001-03-08 2002-03-08 ニコチン酸化合物を使用するレプチンレベル増大のための方法 Expired - Fee Related JP5057353B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US27434901P 2001-03-08 2001-03-08
US60/274,349 2001-03-08
PCT/US2002/007256 WO2002072092A1 (en) 2001-03-08 2002-03-08 Method for increasing leptin levels using nicotinic acid compounds

Publications (3)

Publication Number Publication Date
JP2004519488A JP2004519488A (ja) 2004-07-02
JP2004519488A5 JP2004519488A5 (enExample) 2005-12-22
JP5057353B2 true JP5057353B2 (ja) 2012-10-24

Family

ID=23047813

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2002571051A Expired - Fee Related JP5057353B2 (ja) 2001-03-08 2002-03-08 ニコチン酸化合物を使用するレプチンレベル増大のための方法

Country Status (12)

Country Link
US (2) US6750234B2 (enExample)
EP (1) EP1365762B1 (enExample)
JP (1) JP5057353B2 (enExample)
CN (1) CN1265792C (enExample)
AT (1) ATE409037T1 (enExample)
CA (1) CA2437844C (enExample)
DE (1) DE60229041D1 (enExample)
DK (1) DK1365762T3 (enExample)
ES (1) ES2315358T3 (enExample)
MX (1) MXPA03008096A (enExample)
PT (1) PT1365762E (enExample)
WO (1) WO2002072092A1 (enExample)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1383540T3 (da) 2000-07-31 2009-08-24 Univ Bar Ilan Fremgangsmdåer og farmaceutiske sammensætninger til sårheling
US20040037828A1 (en) 2002-07-09 2004-02-26 Bar-Ilan University Methods and pharmaceutical compositions for healing wounds
ES2315358T3 (es) * 2001-03-08 2009-04-01 University Of Kentucky Research Foundation Metodo para incrementar los niveles de leptina usando compuestos de acido nicotinico.
AU2003299568B2 (en) * 2002-11-27 2010-07-22 Ampio Pharmaceuticals, Inc. Treatment of diseases and conditions mediated by increased phosphorylation
US7736636B2 (en) * 2003-02-12 2010-06-15 Shaker Mousa Method for treating occlusive vascular diseases & wound healing
US7218948B2 (en) 2003-02-24 2007-05-15 Qualcomm Incorporated Method of transmitting pilot tones in a multi-sector cell, including null pilot tones, for generating channel quality indicators
US9544860B2 (en) 2003-02-24 2017-01-10 Qualcomm Incorporated Pilot signals for use in multi-sector cells
US8811348B2 (en) 2003-02-24 2014-08-19 Qualcomm Incorporated Methods and apparatus for generating, communicating, and/or using information relating to self-noise
CA2535029C (en) 2003-08-07 2013-07-16 Healor Ltd. Pharmaceutical compositions and methods for accelerating wound healing
US8969291B2 (en) 2004-10-08 2015-03-03 Enzo Therapeutics, Inc. Methods for decreasing leptin levels or activity for treating inflammation
US8503938B2 (en) 2004-10-14 2013-08-06 Qualcomm Incorporated Methods and apparatus for determining, communicating and using information including loading factors which can be used for interference control purposes
EP1810409A4 (en) 2004-10-14 2012-07-04 Qualcomm Inc METHOD AND DEVICES FOR DETERMINING, TRANSMITTING AND USING INFORMATION THAT MAY BE USED FOR TROUBLESHOOTING PURPOSES
JP2006253769A (ja) * 2005-03-08 2006-09-21 National Institute Of Advanced Industrial & Technology 情報処理システムおよび方法
JP4956534B2 (ja) * 2005-06-24 2012-06-20 アリゾナ・ボード・オブ・リージェンツ・オン・ビハーフ・オブ・ザ・ユニバーシティ・オブ・アリゾナ 女性型脱毛症等の毛髪成長障害の治療方法とそのために有用な組成物
US8367606B2 (en) 2005-08-29 2013-02-05 Healor Ltd. Method and compositions for prevention and treatment of diabetic and aged skin
US20070066512A1 (en) * 2005-09-12 2007-03-22 Dominique Verhelle Methods and compositions using immunomodulatory compounds for the treatment of disorders associated with low plasma leptin levels
US8989084B2 (en) 2005-10-14 2015-03-24 Qualcomm Incorporated Methods and apparatus for broadcasting loading information corresponding to neighboring base stations
US9191840B2 (en) 2005-10-14 2015-11-17 Qualcomm Incorporated Methods and apparatus for determining, communicating and using information which can be used for interference control
US9125093B2 (en) 2005-12-22 2015-09-01 Qualcomm Incorporated Methods and apparatus related to custom control channel reporting formats
US9148795B2 (en) 2005-12-22 2015-09-29 Qualcomm Incorporated Methods and apparatus for flexible reporting of control information
US9451491B2 (en) 2005-12-22 2016-09-20 Qualcomm Incorporated Methods and apparatus relating to generating and transmitting initial and additional control information report sets in a wireless system
US9137072B2 (en) 2005-12-22 2015-09-15 Qualcomm Incorporated Methods and apparatus for communicating control information
US9125092B2 (en) 2005-12-22 2015-09-01 Qualcomm Incorporated Methods and apparatus for reporting and/or using control information
US9338767B2 (en) 2005-12-22 2016-05-10 Qualcomm Incorporated Methods and apparatus of implementing and/or using a dedicated control channel
US8437251B2 (en) 2005-12-22 2013-05-07 Qualcomm Incorporated Methods and apparatus for communicating transmission backlog information
US9119220B2 (en) 2005-12-22 2015-08-25 Qualcomm Incorporated Methods and apparatus for communicating backlog related information
US8514771B2 (en) 2005-12-22 2013-08-20 Qualcomm Incorporated Methods and apparatus for communicating and/or using transmission power information
US9473265B2 (en) 2005-12-22 2016-10-18 Qualcomm Incorporated Methods and apparatus for communicating information utilizing a plurality of dictionaries
US7801589B2 (en) 2005-12-22 2010-09-21 Olympus Corporation In-vivo examination method and in-vivo examination apparatus
US20070253449A1 (en) 2005-12-22 2007-11-01 Arnab Das Methods and apparatus related to determining, communicating, and/or using delay information
US9572179B2 (en) 2005-12-22 2017-02-14 Qualcomm Incorporated Methods and apparatus for communicating transmission backlog information
US20070243882A1 (en) 2006-04-12 2007-10-18 Qualcomm Incorporated Method and apparatus for locating a wireless local area network associated with a wireless wide area network
WO2008026349A1 (fr) * 2006-08-31 2008-03-06 Juridical Foundation Osaka Industrial Promotion Organization Agent thérapeutique destiné au traitement de l'effluvium télogène
DK2120917T3 (da) * 2007-02-28 2014-04-07 Univ Kentucky Res Found Fremgangsmåde til lindring af bivirkninger ved retinsyre-terapi og/eller til forbedring af effektivitet uden at interferere med effektiviteten
EP2523677A2 (en) 2010-01-11 2012-11-21 Healor Ltd. Method for treatment of inflammatory disease and disorder
US11298334B2 (en) * 2016-04-22 2022-04-12 Jc (Wuxi) Company, Inc. Use of isothiocyanate compounds

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4505896A (en) * 1979-04-19 1985-03-19 Elorac, Ltd. Method of treating acne vulgaris and composition
DE3110611A1 (de) * 1981-03-18 1982-10-07 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V., 3400 Göttingen "mitogene der leukozyten und des entzuendungsgewebes:natuerliche leukopoetine zur selektiven anregung der teilung und differenzierung von leukozyten"
GB8330969D0 (en) * 1983-11-21 1983-12-29 Wellcome Found Promoting healing
DE3570598D1 (en) * 1984-11-15 1989-07-06 Nitto Denko Corp Composition for percutaneous administration
US4965252A (en) * 1988-06-28 1990-10-23 Hauser-Kuhrts, Inc. Cholesterol-lowering combination compositions of guar gum and niacin
ATE198830T1 (de) * 1991-03-01 2001-02-15 Univ Florida Verwendung von nikotinanalogen zur behandlung von degenerativen erkrankungen des nervensystems
US5240945A (en) * 1992-02-18 1993-08-31 Warshaw Thelma G Method and compositions for treating acne
US5612382A (en) * 1994-07-15 1997-03-18 Frances B. Fike Composition for percutaneous absorption of pharmaceutically active ingredients
US5496827A (en) * 1994-07-15 1996-03-05 Patrick; Jay Compositions for the transdermal delivery of nutrients
US6068976A (en) * 1995-03-20 2000-05-30 Ligand Pharmaceuticals Incorporated Modulators of ob gene and screening methods therefor
DK0823897T3 (da) * 1995-05-01 2004-12-06 Scarista Ltd Nicotinsyreestere og farmaceutiske præparater indeholdende disse
WO1998052927A1 (en) * 1997-05-19 1998-11-26 Rosemarie Scivoletto Composition for treating skin conditions
AU4672199A (en) * 1998-05-20 1999-12-06 Yale University Modulation of angiogenesis and wound healing
ATE273008T1 (de) * 1998-12-01 2004-08-15 Univ Kentucky Res Found Verwendung von nikotinsäurederivate zur behandlung von dna-schäden bei hautzellen
IT1306141B1 (it) * 1999-05-17 2001-05-30 Giampiero Valletta Composizione per il trattamento del prurito uremico e di forme diprurito non riconducibili a lesioni organiche.
US6326034B1 (en) * 1999-12-22 2001-12-04 Natural Compounds Ltd Natural extracted and synthetic antioxidant compositions
ES2315358T3 (es) * 2001-03-08 2009-04-01 University Of Kentucky Research Foundation Metodo para incrementar los niveles de leptina usando compuestos de acido nicotinico.

Also Published As

Publication number Publication date
DE60229041D1 (de) 2008-11-06
EP1365762A1 (en) 2003-12-03
EP1365762B1 (en) 2008-09-24
ES2315358T3 (es) 2009-04-01
EP1365762A4 (en) 2005-05-25
US20040198776A1 (en) 2004-10-07
PT1365762E (pt) 2008-11-27
WO2002072092A1 (en) 2002-09-19
CN1265792C (zh) 2006-07-26
MXPA03008096A (es) 2005-10-05
US6750234B2 (en) 2004-06-15
CA2437844C (en) 2007-05-15
JP2004519488A (ja) 2004-07-02
HK1065941A1 (en) 2005-03-11
US20020128298A1 (en) 2002-09-12
CN1496260A (zh) 2004-05-12
ATE409037T1 (de) 2008-10-15
DK1365762T3 (da) 2008-11-17
CA2437844A1 (en) 2002-09-19

Similar Documents

Publication Publication Date Title
JP5057353B2 (ja) ニコチン酸化合物を使用するレプチンレベル増大のための方法
Goureau et al. Induction and regulation of nitric oxide synthase in retinal Müller glial cells
Chen et al. Steady augmentation of anti-osteoarthritic actions of rapamycin by liposome-encapsulation in collaboration with low-intensity pulsed ultrasound
EP2033635B1 (en) Use of phenylbutyric acid or salts thereof for treating pruritus
JP2000511561A (ja) 肥満症の処置のためのｃｎｔｆ（毛様体神経成長因子）受容体アクティベーターの使用
Boutari et al. Decreasing lean body mass with age: challenges and opportunities for novel therapies
JP2020526484A (ja) 発毛を調節するための組成物及び方法
JP2012515754A (ja) 神経栄養因子介在疾患の治療
EA022314B1 (ru) Способ лечения псориаза
WO2022001784A1 (zh) 谷氨酰胺酶抑制剂在制备治疗银屑病的药物中的应用
Tsujii et al. % β3adrenergicagonist% Satiety
JP2022504771A (ja) 健康寿命延長を目的とするニコチンアミドリボシド組成物
AU697742B2 (en) Treatment of cytokine growth factor caused disorders
CA2280770C (en) Gene therapy for alleviating erectile dysfunction
JP3098544B2 (ja) サイトカイン活性増強剤およびサイトカインの働きが低下した疾病の治療剤
Tong et al. Differential effects of retinoids on DNA synthesis in calcium-regulated murine epidermal keratinocyte cultures
JP2020515294A (ja) アブラナ科のタンパク質抽出物およびその使用
HK1065941B (en) Use of a nicotinic acid alkyl ester containing an alkyl chain from 8 to 22 carbon atoms for the preparation of a medicament for increasing leptin levels in a subject
US9480675B2 (en) Method for increasing muscle growth by blocking sirtuin activity
EP3194575A1 (en) Process and compositions for achieving mammalian energy balance
JP2007538080A (ja) α−ケト分岐鎖アミノ酸を用いた脳神経細胞内グルタミン酸レベルの低減
Berra et al. Zinc, selenium and skin health: Overview of their biochemical and physiological functions
CA2601999C (en) Method for ameliorating pruritus
JP4503942B2 (ja) 止痒剤
Hofsli et al. Effect of pyridoxine on tumor necrosis factor activities in vitro

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20040630

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20040630

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20080401

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080627

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20080627

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080925

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20081204

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090216

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20090217

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20090324

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20090424

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20110117

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20120725

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20150810

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

Ref document number: 5057353

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees